# Lifeclean International > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/lifecleaninternational). ## Overview LifeClean International develops, manufactures and sells desinfection, decontamination and premium cleaning products through a group structure centered on LifeClean and Kempartner Ocean AB. The business serves regulated end markets in Europe and selected international markets, with production in Vadstena and a mix of own-brand sales, private label manufacturing and licensing arrangements. ## Products & services • High-level desinfection solutions • PFAS decontamination products • Premium cleaning products • Private label chemical manufacturing • Own-brand cleaning products • Licensing of LifeClean technology - **Desinfection products** (35%) — Regulated high-level desinfection products used in healthcare and other controlled environments. - **PFAS remediation** (15%) — Products and solutions for removing PFAS from contaminated surfaces and systems. - **Premium cleaning products** (25%) — Own-brand environmentally profiled detergents, dish and cleaning products. - **Private label manufacturing** (20%) — Contract manufacturing of chemical products for partners under their brands. - **Licensing and technology access** (5%) — Licenses that allow partners to produce and commercialize LifeClean technology in defined geographies. - High-level desinfection solutions - PFAS decontamination products - Premium cleaning products - Private label chemical manufacturing - Own-brand cleaning products - Licensing of LifeClean technology ## Customers LifeClean sells to healthcare and other regulated environments where desinfection and sanitation are system-critical rather than optional. It also serves industrial customers, brand partners and retail consumers through private label, own-brand channels and webshops. The customer base is split between professional buyers that need documented performance and consumer channels that value environmentally profiled cleaning products. - **Healthcare providers** (primary) — Buy desinfection products for continuous use in medically regulated environments where reliability and documentation matter. - **Agriculture and poultry operators** (secondary) — Buy hygiene and biosafety solutions for short-cycle production environments. - **Industrial remediation customers** (secondary) — Buy PFAS decontamination products for contaminated equipment, surfaces and systems. - **Private label partners** (primary) — Buy contract-manufactured chemical products produced at Kempartner Ocean AB's facility. - **Retail consumers and shops** (secondary) — Buy own-brand detergents, dish and cleaning products through stores and webshops. - Hospitals and healthcare operators needing continuous desinfection - Agriculture and poultry operators focused on biosafety - Industrial customers needing PFAS remediation - Brand partners buying private label chemical production - Retail consumers buying own-brand cleaning products ## Geography LifeClean is headquartered in Uddevalla, Sweden, with production activities in Vadstena through Kempartner Ocean AB. The company describes Europe as a key market because of regulatory requirements, while also pursuing licensing and commercialization opportunities outside Europe. Its reported market focus includes Sweden, broader Europe, North America and Asia for PFAS-related applications. - Headquartered in Uddevalla, Sweden - Production site in Vadstena through Kempartner Ocean AB - Europe is a core market because of regulation - Licensing is used to reach markets outside Europe - PFAS opportunities are discussed for North America and Asia ## Strategy LifeClean's strategy is to build value through focused market selection, disciplined resource allocation and partner-based scaling. It prioritizes regulated use cases where desinfection and remediation are structural needs, then expands through local partners and licensing rather than direct sales alone. The approach is designed to improve market access while preserving traceability, compliance and control over product dossiers. - **Partner-based market expansion** (short-term) — Local partners provide distribution, regulatory know-how and faster implementation. - **Licensing outside Europe** (medium-term) — Licensing supports geographic scale with limited capital tied up in operations. - **Regulated end-market focus** (medium-term) — Healthcare, agriculture and remediation demand documented performance and recurring need. - Focus on regulated, system-critical use cases - Scale through local partners and distributors - Use licensing to expand outside Europe - Prioritize projects with clear regulatory pathways - Allocate resources selectively to commercially viable opportunities ## Risks LifeClean is exposed to regulatory, market and supplier risks because its products operate in tightly controlled chemical and biocidal environments. The business also depends on successful commercialization through partners and on continued access to funding and working capital, while PFAS remediation and desinfection markets can be slow to adopt new solutions. Changes in rules, patent outcomes or partner execution could materially affect sales opportunities and product rollout. - **Regulatory compliance risk** [high] — Products must meet biocidal, chemical and medical-device related rules in multiple jurisdictions. - **Intellectual property risk** [high] — Patent applications may not be granted and competitors may infringe or copy formulations. - **Partner execution risk** [medium] — The model relies on distributors, licensees and local partners to commercialize products. - **Liquidity and financing risk** [high] — The company has relied on external funding to support operations and growth initiatives. - **Market adoption risk** [medium] — New remediation and desinfection solutions can face long qualification cycles and slow uptake. - Regulatory approvals are required across multiple jurisdictions - Patent and IP protection may be difficult to enforce - Partner execution affects commercialization speed - Liquidity and financing needs can constrain operations - Supplier and manufacturing dependencies can disrupt delivery ## Accounting LifeClean's reporting is sensitive to revenue timing across private label, own-brand sales and licensing arrangements, which may be recognized differently depending on contract terms and delivery milestones. The company also faces judgment in valuing intangible assets, patents and development-related assets, while financing arrangements and working-capital support can affect balance sheet presentation and cash flow comparability. - **Revenue recognition** — Affects timing of reported sales across product, private label and licensing activities - **Intangible asset impairment** — Could materially affect earnings if recoverability weakens - **Inventory and production accounting** — Affects gross profit and working capital - **Financing and liquidity disclosures** — Affects leverage, liquidity and going-concern analysis - Revenue recognition differs across product sales, private label and licensing - Quarterly results may be affected by uneven project timing and deliveries - Intangible assets and patents require impairment assessment - Financing arrangements can affect cash flow and balance sheet items - Inventory and production costs matter for contract manufacturing --- *Last updated: 2026-08-11T04:04:53.938570+00:00*